BGB-16673

DRUG6 trials

Sponsors

BeOne Medicines AG, BeiGene, BeOne Medicines, M.D. Anderson Cancer Center

Conditions

Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)Chronic lymphocytic leukemia (CLL)Chronic lymphotic leukemia and Small Lymphocytic lymphomaHealthy VolunteersRelapsed or Refractory B-Cell MalignanciesSmall Lymphocytic LymphomaSmall lymphocytic lymphoma (SLL)

Phase 1

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

CompletedNCT06906809

BeiGeneHealthy Volunteers

Start: 2025-04-03End: 2025-10-13Updated: 2026-08-24

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

RecruitingCTIS2024-516234-35-00

BeOne Medicines AGRelapsed or Refractory B-Cell Malignancies

Start: 2025-10-15Target: 99Updated: 2026-01-14

Phase 2

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

RecruitingNCT07508995

M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia (CLL)

Start: 2026-08-20End: 2033-07-01Target: 40Updated: 2026-10-29

Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Active, not recruitingNCT06970743

BeOne MedicinesChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2025-05-29End: 2029-11-30Updated: 2026-08-24

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

RecruitingCTIS2024-518893-15-00

BeOne Medicines AGChronic lymphotic leukemia and Small Lymphocytic lymphoma

Start: 2025-07-29Target: 56Updated: 2026-01-14

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

RecruitingCTIS2025-522860-34-00

BeOne Medicines AGChronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

Start: 2025-12-16Target: 196Updated: 2026-01-21